Processa Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
PCSA$1.87-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
Consolidated Statements of Changes in Stockholders’ Equity
Years Ended December 31, 2023 and 2022
| Additional | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Treasury Stock · Accumulated | |||||||||
| Shares · Amount · Capital · Shares · Amount · Deficit · Total | |||||||||
| Balance at January 1, 2022 | 785,512 | $79 | $62,308,353 | $ | - | $ | - | $(36,823,332) | $25,485,100 |
| Acquisition of treasury stock | - | - | - | (5,000) | (300,000) | - | (300,000) | ||
| Stock-based compensation | 11,890 | 1 | 8,948,712 | - | - | - | 8,948,713 | ||
| Shares issued in connection with the Purchase Agreement with Lincoln Park | 6,181 | 1 | 449,999 | - | - | - | 450,000 | ||
| Shares issued in connection with license agreement | 5,000 | - | 400,000 | - | - | - | 400,000 | ||
| Shares withheld to pay income taxes on stock-based compensation | (1,809) | (1) | (88,842) | - | - | - | (88,843) | ||
| Net loss | - | - | - | - | - | (27,424,229) | (27,424,229) | ||
| Balance, January 1, 2023 | 806,774 | 80 | 72,018,222 | (5,000) | (300,000) | (64,247,561) | 7,470,741 | ||
| Stock-based compensation | 6,945 | 1 | 1,060,338 | - | - | - | 1,060,339 | ||
| Shares issued in connection with capital raises, net of transaction costs | 421,611 | 42 | 6,352,035 | - | - | - | 6,352,077 | ||
| Warrant granted in connection with a consulting agreement | - | - | 1,310,875 | - | - | - | 1,310,875 | ||
| Settlement of stock award | - | - | (52,746) | - | - | - | (52,746) | ||
| Other | 55,670 | 6 | (30,613) | - | - | - | (30,607) | ||
| Net loss | - | - | - | - | - | (11,121,520) | (11,121,520) | ||
| Balance, December 31, 2023 | 1,291,000 | $129 | $80,658,111 | (5,000) | $(300,000) | $(75,369,081) | $4,989,159 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.